Cost of living: Which are the cheapest and most expensive countries in Europe?
But how can we best compare prices across Europe? And what are the most expensive and cheapest countries across the continent?
Price level indices are a good way to help us understand how expensive or cheap goods and services are in each country. They compare national price levels to the EU average and are calculated using Purchasing Power Parities (PPPs).
According to Eurostat, PPPs act like an artificial common currency, as they show how much people can buy with the same amount of money across countries.
The results are based on price surveys covering more than 2,000 consumer goods and services, conducted across 36 European countries.
There are several price level indices that compare the cost of different goods and services — such as food, drink, clothing, hotels, and more. In addition to these individual or group indices, there are two main indicators that show the 'overall' price level of consumer goods and services:
One is actual individual consumption (AIC), which measures all goods and services actually consumed by households. It includes consumer goods and services purchased directly by households, as well as services provided by non-profit institutions. The indicator also includes services provided by the government for individual consumption such as health and education services.
Another indicator is household final consumption expenditure (HFCE), which studies total spending on individual goods and services by resident households.
In other words, AIC looks at what households use — including services they don't directly pay for — and HFCE shows what they spend money on.
Eurostat notes that AIC is often used in international comparisons, as it captures more than the narrower concept of household consumption. Euronews has therefore used AIC figures for comparisons, although consumption data is also included in the chart.
As of 2024, out of 36 countries, Switzerland is the most expensive, with prices at 184% of the EU average — 84% higher than the average.
Turkey is the cheapest, with prices at 47% of the EU average, meaning they are 53% lower than the EU average.
This makes Switzerland 3.9 times as expensive as Turkey, revealing the sharp contrast in price levels across Europe.
A price level above 100 means a country is more expensive than the EU average; below 100 means it's cheaper.
In the EU, Luxembourg is the most expensive country, with prices 51% higher than the EU average.
Bulgaria and Romania are the cheapest members, at 57% of the EU average.
This means Luxembourg is about 2.7 times as expensive as Bulgaria and Romania, showing a significant but smaller gap compared to the difference between Switzerland and Turkey.
Ten EU countries have prices above the EU average. Denmark (143%) and Ireland (141%) follow Luxembourg as the most expensive.
Among the EU's four largest economies, Germany (109%) and France (108%) are slightly above average, while Italy (98%) and Spain (91%) are below.
Western and Northern European countries tend to have high price levels. Switzerland, Iceland, Luxembourg, Denmark, Ireland, Norway, and Finland all show significantly above-average prices. These are generally high-income countries with strong currencies and higher living costs.
All five Nordic countries— Denmark, Finland, Sweden, Norway, and Iceland — also consistently rank near the top.
In contrast, Central and Eastern European countries generally have lower price levels. Romania, Bulgaria, Hungary, Poland, and the Baltic States — Latvia, Lithuania, and Estonia — are all below the EU average. These regions typically record lower labour costs.
Price levels are also lower in the EU candidate countries. They included Turkey, North Macedonia, Albania, Serbia, and Bosnia and Herzegovina.
Two European Free Trade Association (EFTA) countries — Switzerland and Iceland —rank first and second in 2024, with Norway in sixth place.
In a 2018 analysis based on 2017 figures, Lars Svennebye of the EFTA Statistical Office explained that high workforce productivity and corresponding high salaries were key factors behind the high price levels in EFTA countries.
Filippo Pallotti, PhD Candidate in Economics at University College London, told Euronews Business that across Europe, the most expensive countries to live in tend to be the most productive. 'Productivity gains in tradable sectors (like manufacturing and tech) drive up wages economy-wide - even in non-tradable sectors such as hairdressing, hospitality, and real estate, where productivity growth is slower,' he said.
Comparing the highest and lowest ends of the EU, Pallotti pointed out that hourly labour costs mirror price levels — around €55 in Luxembourg, €50 in Denmark, and just €11 in Bulgaria. 'But when comparing coffee at €4 in Copenhagen versus €1 in Sofia, it's the interplay of strong tradable-sector productivity and the resulting elevated wages across all sectors that chiefly explains the gap." he added.
Pallotti also noted that beyond wages, productivity itself stems from several key factors: capital intensity, technology adoption, human capital, institutional quality, infrastructure, and foreign investment - including skilled management and talent inflows. Other contributing factors - VAT and indirect taxes, cost of regulation, urban density, transport infrastructure, and even currency valuations - play roles in shaping prices.
Individual or household incomes are not included in price level comparisons. 'These figures are pure price comparisons of goods and services. They do not take the level of wages, salaries or other measures of personal income into account,' Lars Svennebye told Euronews Business.
This means that someone living in a country with a high price level may still be able to buy more goods and services than someone in a country with a lower price level, depending on income.
Price levels vary significantly across different categories. For example, the price level for alcohol and tobacco in the EU was nearly three times higher in Ireland (205%), the most expensive country, than in Bulgaria (69%), the cheapest.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
What investors need to know about Trump's Mexico, EU threats
President Trump threatened a 30% tariff on some goods from Mexico and the EU. In the video above, Yahoo Finance Washington Correspondent Ben Werschkul and Innovator Capital Management chief investment strategist Tim Urbanowicz discuss the news and what it means for markets. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Ben, let's start with you. Tell us the latest here with some of these new numbers being thrown out there. For sure. Yeah. I think a good rule of thumb maybe for investors is that when a deadline is still a few weeks away, that's kind of one of the peak headline risk times. And so, I think we're seeing a lot of that. That's a lot of what's going on here in all this back and forth over the weekend and this morning. Um, and we're seeing it from both sides. And this obviously comes after Trump's surprise announcement of 30% tariffs on the European Union even as negotiators continue to talk. It's worth noting also that other comments this morning from Europeans, from the European trade commissioner, this came in a bunch of comments to reporters were more optimistic that talks are going to continue. And he said, quote, he sensed there's, they are approaching, quote, a good outcome for both sides. So there is still, that, that sort of points to me to the overall landscape here with Europe, which is that there is the parameters of a deal. They're getting closer. They clearly came up short last week ending with this 30% this 30% letter. But there's still a sense of progress there and just sort of refocused on an August 1st deadline. From the White House side, we're kind of seeing a similar dynamic. We're seeing kind of a bluster from Trump. His, his comment this morning was that, um, more broadly was that nations should sort of be happy, um, with with with with his letters coming out and should be sort of acknowledge that they ripped off the US. I, I'm pretty skeptical that any country's going to take that too seriously, but we're seeing a lot of signs from Trump's aides that this is essentially a negotiating ploy. Um, Kevin Hassett was telling reporters this morning at the White House that yes, negotiations are going to keep going with Europe, with Canada, with Mexico, which are two other major recipients of these kind of surprise letters we've seen in the last couple days. Um, and Tim, I want to bring you into this. Is this why we're not seeing markets react more because again, you know, participants are not necessarily taking it seriously that these are actually going to go into effect. Well, Julie, I think investors need to take the president serious on this. Uh, yes, there will be negotiations. We think those negotiations are going to take a lot longer, uh, than is currently priced in right now. They're not going to be easy, but at the end of the day, the destination is higher tariffs and I don't think investors have digested that yet. The destination is higher tariffs. You look at what the president wants to accomplish with these tariffs. He wants to close those trade deficits, okay? That's big. The only way you possibly do that is to weaken the dollar. So that, that, that's, that's a big component of this. We need to be paying attention to that and he wants to bring manufacturing back to the US. How do you do that? You have to make the cost of producing goods overseas more expensive. So for investors, there's a lot of implications. All signs on our front point to higher inflation. Um, Ben, and I want to bring you back into this because to the point that Tim was just making, I was looking at some of the latest numbers from the Budget Lab at Yale University, which I know all of us have been tracking because they, they are sort of keeping track of the tariffs and the effect. They said the effective US tariff rate under President Trump has risen to 16.6% from 2.5%. And if all of these tariffs he's now talked about going to effect, it would be 20.6% on August 1st. You just heard what, what Tim was saying here. What, you know, and it is interesting just try and read between the lines as to what all the advisors are saying, but, you know, what's the sort of takeaway as to how realistic it is? Yeah, I mean, I think the, the takeaway, Tim, I think Tim is exactly right that there's reason to be skeptical of these top level lines, but I also think the, the end is here is, is a, is a higher tariff level. So somewhere between those two budget lab numbers is probably where this ends up on August 2nd, once, once these are in effect. The sort of taco trade idea that Trump always back chickens out is true to a certain extent, but he does, he does follow through on some of his promises. So say he, say he, say he backs away on Canada for a little bit, but goes forward on Mexico. There's all these different factors here, but I do think it's right that the bottom line here is that tariffs are, are rising to some extent. The question is how much as Trump is supremely focused, as Tim also mentioned, on this revenue question. He really wants, the president really wants revenues to be a huge component of the budget, of the budget going forward. It's growing at incredible paces. It's still got a long ways to go, and he'd have to raise tariffs a lot more to, to accomplish those goals. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Automated Immunoassay Analyzers Market Valuation Poised to Surpass US$ 74.59 Billion by 2033
Demand for automated immunoassay analyzers surges across laboratories and clinics, driven by soaring test volumes and rigorous quality expectations. Consequently, data-enabled platforms, local production alliances, and point-of-care integration position the market for remarkable long-term profitability. Chicago, July 14, 2025 (GLOBE NEWSWIRE) -- The global automated immunoassay analyzers market was valued at US$ 23.12 billion in 2024 and is expected to reach US$ 74.59 billion by 2033, growing at a CAGR of 13.90% during the forecast period 2025–2033. The COVID-19 pandemic permanently elevated baseline laboratory workloads, and 2024 procurement logs from the ten largest U.S. health systems confirm that routine immunoassay volumes now exceed 2.3 billion tests annually—an increase of more than 600 million tests versus 2019. Sustained demand for cardiac biomarkers, high-sensitivity thyroid panels, and multiplex respiratory assays has pushed core-lab managers to favor consolidated instrumentation capable of running 400–600 samples without manual loading. Consequently, the automated immunoassay analyzers market is experiencing unprecedented inquiry levels from public and private facilities alike, with many buyers stipulating 24/7 unattended operation as a mandatory tender requirement. Laboratory directors also cite soaring nurse-to-patient ratios as an impetus to replace semi-automated systems that still require tube decapping or reagent re-constitution. Get Instant Access to Sample Pages: Outside North America, similar patterns are evident. India's National Health Mission reported 370 million immunoassay tests reimbursed in fiscal 2023, driven chiefly by antenatal screening and sepsis triage. Meanwhile, Germany's DRG data show troponin-I orders rising by 11 million test-units between 2022 and 2023, underscoring a Europe-wide pivot toward faster cardiac rule-out protocols. These concrete throughput figures, rather than abstract growth percentages, capture the operational urgency now propelling new installations in the market. Investors looking at laboratory infrastructure can therefore bank on test-volume momentum that appears structurally entrenched rather than merely cyclical. Key Findings in Automated immunoassay Analyzers Market Market Forecast (2033) US$ 74.59 Billion CAGR 13.90% Largest Region (2024) North America (35%) By Product Type Chemiluminescence (53%) By Application Infectious Diseases (30%) By End Users Hospitals (34%) Top Drivers Chronic disease prevalence increased 68% driving automated immunoassay demand 65% laboratories depend on automated systems for high-throughput testing 67% hospitals prefer automated immunoassay analyzers for early detection Top Trends AI-integrated automated immunoassay analyzers adoption increased by 46% globally Point-of-care immunoassay analyzers witnessed 49% growth in healthcare facilities Multiplex automated immunoassay analyzers rose 41% for simultaneous testing Top Challenges 37% diagnostic labs report automated immunoassay analyzer integration difficulties 39% small laboratories cite automated immunoassay analyzer budget constraints 31% efficiency gap exists across multi-vendor immunoassay analyzer platforms Innovations Elevate Throughput Sensitivity and Workflow In Modern Laboratories During 2023-2024, vendors introduced a wave of platform refreshes that materially reshape the automated immunoassay analyzers market. Roche's cobas® pro integrated solution, for example, processes up to 2,200 results per hour by chaining two e 801 modules to a shared sample container—effectively doubling the output of its previous-generation layout. Abbott's Alinity i 'Series 2' firmware update also trims turnaround time for high-volume thyroid-stimulating hormone assays from 18 minutes to 10 minutes, a gain accomplished by re-optimizing on-board incubation paths. These incremental yet critical advances translate directly into shorter emergency-department holdovers and improve clinician satisfaction, two metrics now embedded in most U.S. value-based purchasing contracts. Equally transformative are sensitivity upgrades. DiaSorin's LIAISON® XL now detects vitamin-D levels down to 4 ng/mL, supporting earlier osteopenia intervention. Beckman Coulter's new Access SARS-CoV-2 IgM assay boasts a limit of detection below 0.1 AU/mL, enabling more reliable post-infection surveillance. The push toward finer analytical performance is reinforced by oncology: HER-2 quantitative monitoring demands coefficient-of-variation values under 3.0, forcing manufacturers to tighten temperature-control algorithms and reagent-mixing kinetics. These concrete engineering milestones highlight how continuous R&D investment is not mere marketing theater but rather the practical engine sustaining long-term leadership within the automated immunoassay analyzers market. Regulatory Landscape and Quality Standards Steer Procurement and Implementation Decisions Risk-based regulation is intensifying worldwide, and its ripple effect can be felt across the automated immunoassay analyzers market. The European Union's In Vitro Diagnostic Regulation (IVDR) fully entered its transitional enforcement phase in May 2024, immediately re-classifying over 430 legacy immunoassays into higher-risk categories that require notified-body scrutiny. Vendors that completed IVDR technical documentation early—among them Roche, Abbott, and bioMérieux—gained a tangible sales edge because hospital buyers increasingly bundle analyzer hardware with CE-accredited reagent menus. In the United States, the FDA's 2024 revised draft guidance on laboratory-developed tests mandates manufacturer-validated performance claims for any assay run on automated platforms; this change is forecast to shift considerable test volume from home-brewed ELISA benches onto fully cleared instruments. Quality management frameworks are evolving in tandem. College of American Pathologists accreditation checklists now include a dedicated line-item for 'automated maintenance logs with vendor-validated electronic signatures,' effectively compelling laboratories to select analyzers capable of exporting non-editable PDF files. In China, the National Medical Products Administration added 'loop calibration verification' to its compulsory inspection list, emphasizing metrological traceability. Taken together, these regulatory nudges penalize vendors that lack end-to-end compliance infrastructure, and they amplify the premium placed on fully documented systems within the automated immunoassay analyzers market. Health Economics Reveal Cost Efficiency and Staffing Impact Of Automation Total cost-of-ownership audits conducted by five U.S. academic medical centers in 2023 show that swapping three medium-throughput analyzers for one high-end automated immunoassay line yielded an average US$ 980,000 in annual labor savings, primarily by eliminating third-shift technologist overtime. The same studies documented reagent waste reductions of 8.4 million test-cups over 12 months, thanks to real-time on-board inventory tracking. Even without referencing market-size figures, such micro-economic data points reveal why procurement committees consistently green-light capital expenditure in the automated immunoassay analyzers market. Beyond direct savings, opportunity costs are substantial. A Midwest health system calculated that freeing 2.6 full-time equivalents previously tied to manual tube sorting allowed the hospital to expand a profitable allergy panel that netted an additional US$ 3.2 million in test revenue during 2023. Similar math underpins adoption in Latin America, where private diagnostics chains regularly publish analyzer uptime records exceeding 98,000 continuous operating minutes between unplanned service calls. By quantifying concrete dollar and labor benefits—not abstract CAGR curves—hospital CFOs can more accurately benchmark payback periods, thereby reinforcing the fiscal logic of investments across the automated immunoassay analyzers market. Emerging Markets Showcase Rapid Infrastructure Expansion and Local Manufacturing Partnerships National healthcare initiatives are rewriting the geographic demand map for the automated immunoassay analyzers market. Brazil's Programa Mais Saúde, updated in January 2024, allocated funding to equip 150 new regional laboratories; the first tranche of tenders requires 800-test/hour immunoassay lines with chemiluminescent technology. In parallel, Indonesia's Ministry of Health confirmed the delivery of 420 Abbott ARCHITECT platforms to public hospitals under its 'Sehat Bersama' modernization program, dramatically increasing rural testing capacity for hepatitis and HIV. These publicly disclosed procurement figures illustrate a decisive shift from manual ELISA plates toward turnkey automation. Local manufacturing alliances are accelerating this momentum. In 2024, China's Mindray signed a joint-venture agreement with Egypt's SEDICO to assemble the CL-900i analyzer in Sixth of October City, ensuring shorter delivery lead times and compliance with new import-substitution mandates. Meanwhile, Indian contract manufacturer SkanRay began producing control and calibration kits for Beckman Coulter's Access series, reducing per-test logistics costs by roughly US$ 0.18. Such initiatives blend industrial policy with pragmatic supply-chain risk mitigation, making them a cornerstone growth lever within the automated immunoassay analyzers market. Point Of Care Convergence Creates Hybrid Systems For Decentralized Testing The border between core laboratory and near-patient testing continues to blur, reshaping product design across the automated immunoassay analyzers market. Siemens Healthineers' Atellica® VTLi, a handheld high-sensitivity troponin device launched globally in 2024, delivers a quantitative result in eight minutes while automatically syncing data to the hospital's central LIS. When paired with the company's Atellica® IM module, laboratories can now standardize cardiac assays from emergency bay to central lab, eliminating cross-platform calibration discrepancies. Similar hybrid configurations are emerging in primary-care networks, where desktop units such as the bioMérieux VIDAS® Duo establish bridgeheads for decentralized thyroid and fertility screening. Capital planners find the economics compelling: each avoided sample transport can save roughly US$ 9 in courier and packaging costs, according to a 2024 analysis by the United Kingdom's National Pathology Exchange. Moreover, reduced pre-analytic time translates into earlier clinical decisions, directly feeding value-based reimbursement metrics. As health systems intensify their outreach to ambulatory surgery centers and retail clinics, vendors able to architect seamless core-to-POC ecosystems will capture the lion's share of incremental placements in the automated immunoassay analyzers market. Data Integration, AI, and Cloud Services Power Predictive Maintenance Ecosystems Software has become a decisive differentiator in the automated immunoassay analyzers market. Beckman Coulter's DxONE Insights platform now aggregates anonymized performance data from more than 14,000 analyzers worldwide, using gradient-boosted AI models to predict reagent lot failures up to 36 hours in advance. Early pilots at a 1,200-bed Seoul hospital shaved 4.7 unplanned downtime hours per month, preserving continuous STAT turnaround. Similarly, Roche's cobas® link cloud pushes firmware patches in under three minutes, completing tasks that once required an on-site engineer visit and a two-hour shutdown. Such quantifiable uptime improvements offer laboratories a compelling hedge against staff shortages and reactive maintenance costs. Interoperability is equally critical. The latest HL7® FHIR modules released in February 2024 allow direct analyzer-to-EHR token exchange, enabling discrete outcome reporting for increasingly data-rich multiplex assays. This connectivity extends to quality control: CLIA-mandated Levy–Jennings charts now populate automatically, boosting audit readiness. Because software subscription fees are typically booked under operating rather than capital budgets, IT-savvy procurement teams gain new levers for spreading cash outflow while still advancing technical capabilities. As digital health maturity rises, the data layer is fast becoming a primary battleground, intensifying competitive dynamics within the automated immunoassay analyzers market. Get Expert Validation Before You Purchase: Competitive Landscape Highlights Strategic Alliances, Differentiated Portfolios, User Centric Design Competitive intensity has reached a new pitch in 2024, with mergers and strategic alliances reshaping the automated immunoassay analyzers market. Thermo Fisher Scientific's acquisition of specialty assay developer Olink unlocks a 1,500-analyte proteomics menu that will be ported onto its Indiko™ platform over the next 18 months. Meanwhile, Siemens Healthineers and Fujifilm announced a co-development pact targeting oncology markers optimized for both chemiluminescent and photon-counting detection, a dual-format strategy designed to hedge technology risk. Such tie-ups reflect an industry consensus that reagent breadth, not just hardware specs, will determine long-run customer retention. User-centric engineering is also front-and-center. Mindray's CL-8000i introduces LED-illuminated reagent bays viewable through tempered glass, allowing technologists to confirm inventory without opening doors—an innovation that shaved 12 seconds off each loading cycle during a 2024 usability trial. Alere's next-gen Triage® X analyzer features voice-guided maintenance routines, cutting onboarding time for new hires by three hours. Across bids, hospitals increasingly award 'human-factor' points that can sway purchasing decisions when technical scores are otherwise neck-and-neck. These developments underscore how ergonomics, assay partnerships, and digital ecosystems collectively mold competitive positioning in the automated immunoassay analyzers market, setting the stage for continuous evolution well beyond 2025. Automated Immunoassay Analyzers Market Key Players: Beckman Coulter Sysmex Corporation Abbott Laboratories Fujirebio Abcam PerkinElmer Roche Diagnostics Ortho Clinical Diagnostics Hologic Quidel Corporation Siemens Healthineers Molecular Devices bioMérieux Thermo Fisher Scientific Danaher Corporation Other Prominent Players Key Segmentation: By Product Immunofluorescence Chemiluminescence Enzyme Linked Fluorescent System Radioimmunoassay By Application Infectious Diseases Endocrinology Drug Monitoring Chronic Diseases Allergy Testing By End User Academic Research Institutes Biotech And Pharma Companies Hospitals Diagnostic Test Laboratories Others By Region Europe Asia Pacific Middle East Africa South America Customize the Data Scope to Match Your Objectives: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Fox News
42 minutes ago
- Fox News
Trump, Rutte announce 'really big' NATO arms package amid new 50 day deadline
President Donald Trump on Monday confirmed that the U.S. has agreed to sell arms to NATO just moments after he said Russian President Vladimir Putin has 50 days to secure a peace deal with Ukraine or face "100%" tariffs. NATO Secretary-General Mark Rutte said Trump called him on Thursday to confirm he wanted to enter into a deal with NATO allies to sell them arms for aid to Ukraine. Trump said billions of dollars worth of U.S. arms would be purchased from allies like Germany, Finland and Denmark that will be "quickly distributed" to Ukraine. "This is really big," Rutte told reporters from the Oval Office sitting alongside Trump. Rutte, who said the decision was built on the "tremendous success" of last month's NATO summit when nearly every nation in the alliance agreed to increase their defense spending to reach 5% of their nation's GDP, called the move "logical." Check back on this developing story.